Short- and long-term outcome and quality of life assessment in dogs undergoing transvenous coil embolization of congenital intrahepatic portosystemic shunts.

PTCE with medical management provides effective long-term treatment for canine cIHPSS with improved survival and quality of life.

This retrospective and prospective study evaluated 61 dogs with congenital intrahepatic portosystemic shunts (cIHPSS) treated with percutaneous transcatheter coil embolization (PTCE). Median follow-up was 769 days with median survival of 1496 days. One-, two-, and five-year survival rates were 83%, 66%, and 54%, respectively. The congenital portosystemic shunt severity score (Hr-CPSS) significantly improved from median 25 pre-diagnosis to 5 post-PTCE (p<0.001). Health-related quality of life (Hr-QoL) scores substantially improved post-PTCE (median 100) compared to pre-diagnosis (35) and post-medical management (75). At final follow-up, 56% of dogs required ongoing medical management and/or specialized diet. PTCE combined with targeted medical therapy provided significant improvement in clinical signs, quality of life, and long-term survival, representing an effective minimally invasive treatment option for canine cIHPSS.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.